Christopher M Counter

List of Publications by Year
in descending order

92 papers	12,835 citations	57758 44 h-index	51608 86 g-index
98 all docs	98 docs citations	98 times ranked	15057 citing authors

#	Article	IF	Citations
1	Creation of human tumour cells with defined genetic elements. Nature, 1999, 400, 464-468.	27.8	2,148
2	hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization. Cell, 1997, 90, 785-795.	28.9	1,689
3	A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biology, 2004, 6, 308-318.	10.3	687
4	Erk2 Phosphorylation of Drp1 Promotes Mitochondrial Fission and MAPK-Driven Tumor Growth. Molecular Cell, 2015, 57, 537-551.	9.7	509
5	The telomere hypothesis of cellular aging. Experimental Gerontology, 1992, 27, 375-382.	2.8	465
6	Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature, 2014, 509, 492-496.	27.8	425
7	Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene, 1998, 16, 1217-1222.	5.9	383
8	Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes and Development, 2002, 16, 2045-2057.	5.9	373
9	Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nature Biotechnology, 2002, 20, 587-591.	17.5	351
10	Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes and Development, 2007, 21, 1714-1719.	5.9	346
11	Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell, 2005, 7, 533-545.	16.8	330
12	RALA and RALBP1 regulate mitochondrial fission atÂmitosis. Nature Cell Biology, 2011, 13, 1108-1115.	10.3	327
13	Tumour maintenance is mediated by eNOS. Nature, 2008, 452, 646-649.	27.8	289
14	A model for RAS mutation patterns in cancers: finding the sweet spot. Nature Reviews Cancer, 2018, 18, 767-777.	28.4	266
15	The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis. Cancer Research, 2008, 68, 7561-7569.	0.9	234
16	A Novel Role for Copper in Ras/Mitogen-Activated Protein Kinase Signaling. Molecular and Cellular Biology, 2012, 32, 1284-1295.	2.3	226
17	Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. Current Biology, 2006, 16, 2385-2394.	3.9	212
18	Blood vessels engineered from human cells. Lancet, The, 2005, 365, 2122-2124.	13.7	211

#	Article	IF	Citations
19	Human arteries engineered in vitro. EMBO Reports, 2003, 4, 633-638.	4.5	177
20	Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell, 2005, 8, 381-392.	16.8	168
21	N-Terminal Domains of the Human Telomerase Catalytic Subunit Required for Enzyme Activity in Vivo. Molecular and Cellular Biology, 2001, 21, 7775-7786.	2.3	162
22	Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model. Journal of Biological Chemistry, 2003, 278, 15951-15957.	3.4	134
23	Rare Codons Regulate KRas Oncogenesis. Current Biology, 2013, 23, 70-75.	3.9	132
24	Loss of hPot1 Function Leads to Telomere Instability and a cut-like Phenotype. Current Biology, 2004, 14, 2264-2270.	3.9	128
25	A Genetic Porcine Model of Cancer. PLoS ONE, 2015, 10, e0128864.	2.5	128
26	The roles of telomeres and telomerase in cell life span. Mutation Research - Reviews in Genetic Toxicology, 1996, 366, 45-63.	2.9	116
27	The Nucleolar Localization Domain of the Catalytic Subunit of Human Telomerase. Journal of Biological Chemistry, 2002, 277, 24764-24770.	3.4	110
28	A Network of Genetic Events Sufficient to Convert Normal Human Cells to a Tumorigenic State. Cancer Research, 2005, 65, 9824-9828.	0.9	102
29	Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA. Molecular and Cellular Biology, 2010, 30, 508-523.	2.3	100
30	C-Terminal Regions of the Human Telomerase Catalytic Subunit Essential for In Vivo Enzyme Activity. Molecular and Cellular Biology, 2002, 22, 6234-6246.	2.3	98
31	Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. Cancer Research, 2017, 77, 6240-6252.	0.9	98
32	Oncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2008, 8, 22-27.	3.4	83
33	Genetic Modeling of Human Rhabdomyosarcoma. Cancer Research, 2005, 65, 4490-4495.	0.9	79
34	A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Reports, 2017, 20, 999-1015.	6.4	77
35	Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. Journal of Clinical Investigation, 2018, 128, 3806-3812.	8.2	73
36	Defining the Cooperative Genetic Changes That Temporally Drive Alveolar Rhabdomyosarcoma. Cancer Research, 2008, 68, 9583-9588.	0.9	71

#	Article	IF	Citations
37	Rare codons capacitate Kras-driven de novo tumorigenesis. Journal of Clinical Investigation, 2015, 125, 222-233.	8.2	71
38	Characterization of Interactions between PinX1 and Human Telomerase Subunits hTERT and hTR. Journal of Biological Chemistry, 2004, 279, 51745-51748.	3.4	69
39	Rescue of an hTERT Mutant Defective in Telomere Elongation by Fusion with hPot1. Molecular and Cellular Biology, 2004, 24, 3552-3561.	2.3	67
40	In Vivo Regulation of hTERT Expression and Telomerase Activity by Androgen.. Journal of Urology, 2003, 170, 615-618.	0.4	66
41	Telomerase Reverse Transcriptase Is Required for the Localization of Telomerase RNA to Cajal Bodies and Telomeres in Human Cancer Cells. Molecular Biology of the Cell, 2008, 19, 3793-3800.	2.1	65
42	The PAX3-FKHR Fusion Gene of Rhabdomyosarcoma Cooperates with Loss of p16INK4A to Promote Bypass of Cellular Senescence. Cancer Research, 2007, 67, 6691-6699.	0.9	57
43	Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nature Communications, 2018, 9, 3646.	12.8	56
44	Targeting eNOS in Pancreatic Cancer. Cancer Research, 2012, 72, 4472-4482.	0.9	54
45	hSnm1B Is a Novel Telomere-associated Protein. Journal of Biological Chemistry, 2006, 281, 15033-15036.	3.4	46
46	Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. Clinical Cancer Research, 2018, 24, 4271-4281.	7.0	45
47	Putative Telomere-Recruiting Domain in the Catalytic Subunit of Human Telomerase. Molecular and Cellular Biology, 2003, 23, 3237-3246.	2.3	44
48	A Genetically Defined Normal Human Somatic Cell System to Study Ras Oncogenesis In Vivo and In Vitro. Methods in Enzymology, 2006, 407, 637-647.	1.0	44
49	Genomics and Clinical Medicine: Rationale for Creating and Effectively Evaluating Animal Models. Experimental Biology and Medicine, 2004, 229, 866-875.	2.4	39
50	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nature Communications, 2017, 8, 15617.	12.8	38
51	cPLA2 Regulates the Expression of Type I Interferons and Intracellular Immunity to Chlamydia trachomatis. Journal of Biological Chemistry, 2010, 285, 21625-21635.	3.4	37
52	Sec5 and Exo84 Foster Oncogenic Ras-Mediated Tumorigenesis. Molecular Cancer Research, 2010, 8, 223-231.	3.4	34
53	Distinct Functions of POT1 at Telomeres. Molecular and Cellular Biology, 2008, 28, 5251-5264.	2.3	33
54	Telomere shortening in cultured autografts of patients with burns. Lancet, The, 2003, 361, 1345-1346.	13.7	32

#	Article	IF	Citations
55	ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis, 2009, 30, 1841-1847.	2.8	31
56	INHIBITION OF TELOMERASE IS RELATED TO THE LIFE SPAN AND TUMORIGENICITY OF HUMAN PROSTATE CANCER CELLS. Journal of Urology, 2001, 166, 694-698.	0.4	28
57	POT1 Association with TRF2 Regulates Telomere Length. Molecular and Cellular Biology, 2009, 29, 5611-5619.	2.3	27
58	Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nature Communications, 2020, 11, 1800.	12.8	25
59	Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene, 2002, 21, 7121-7125.	5.9	24
60	Genetically Engineered Human Cancer Models Utilizing Mammalian Transgene Expression. Cell Cycle, 2006, 5, 1074-1079.	2.6	24
61	Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. Nature Communications, 2021, 12, 5248.	12.8	24
62	Use of Retrovirus Expression of Interfering RNA to Determine the Contribution of Activated Kâ€Ras and Ras Effector Expression to Human Tumor Cell Growth. Methods in Enzymology, 2006, 407, 556-574.	1.0	21
63	PinX1 Localizes to Telomeres and Stabilizes TRF1 at Mitosis. Molecular and Cellular Biology, 2012, 32, 1387-1395.	2.3	18
64	Decreased tumorigenesis in mice with a Kras point mutation at C118. Nature Communications, 2014, 5, 5410.	12.8	17
65	Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. Oncotarget, 0, 7, 42385-42392.	1.8	16
66	The Protein hSnm1B Is Stabilized When Bound to the Telomere-binding Protein TRF2. Journal of Biological Chemistry, 2008, 283, 23671-23676.	3.4	14
67	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Reports, 2021, 37, 110060.	6.4	14
68	Wild-type Kras expands and exhausts hematopoietic stem cells. JCI Insight, 2018, 3, .	5.0	13
69	Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer. PLoS ONE, 2015, 10, e0140253.	2.5	12
70	Characterization of the porcine ATM gene: Towards the generation of a novel non-murine animal model for Ataxia-Telangiectasia. Gene, 2007, 405, 27-35.	2.2	11
71	Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway. Scientific Reports, 2020, 10, 22166.	3.3	11
72	Distinct responses to rare codons in select Drosophila tissues. ELife, 2022, 11, .	6.0	11

#	Article	IF	Citations
73	Breaking up is hard to do. Small GTPases, 2011, 2, 329-333.	1.6	10
74	Signaling levels mold the RAS mutation tropism of urethane. ELife, 2021, 10, .	6.0	10
75	A Method to Generate Genetically Defined Tumors in Pigs. Methods in Enzymology, 2008, 439, 39-51.	1.0	9
76	Tethering Telomeric Double- and Single-stranded DNA-binding Proteins Inhibits Telomere Elongation. Journal of Biological Chemistry, 2008, 283, 6935-6941.	3.4	8
77	Reduced HRASG12V-Driven Tumorigenesis of Cell Lines Expressing KRASC118S. PLoS ONE, 2015, 10, e0123918.	2.5	8
78	Creating Porcine Biomedical Models Through Recombineering. Comparative and Functional Genomics, 2004, 5, 262-267.	2.0	7
79	Genetic Modeling of Rasâ€Induced Human Rhabdomyosarcoma. Methods in Enzymology, 2008, 438, 419-427.	1.0	7
80	Exploiting codon usage identifies intensity-specific modifiers of Ras/MAPK signaling in vivo. PLoS Genetics, 2020, 16, e1009228.	3.5	7
81	Leveling the Playing Field. Molecular Cell, 2004, 15, 491-492.	9.7	5
82	Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice. PLoS ONE, 2016, 11, e0167205.	2.5	5
83	Cell Cycle Regulated Phosphorylation of the Telomere-Associated Protein TIN2. PLoS ONE, 2013, 8, e71697.	2.5	4
84	Utility of Telomerase-pot1 Fusion Protein in Vascular Tissue Engineering. Cell Transplantation, 2010, 19, 79-87.	2.5	2
85	Using BioID to Characterize the RAS Interactome. Methods in Molecular Biology, 2021, 2262, 271-280.	0.9	2
86	Blood vessels engineered from human cells â€“ Authors' reply. Lancet, The, 2005, 366, 892-893.	13.7	1
87	Snm1B Interacts with PSF2. PLoS ONE, 2012, 7, e49626.	2.5	1
88	A Role for eNOS in Oncogenic Ras-Driven Cancer. , 2010, , 23-38.		1
89	From Bread to Bedside: What Budding Yeast has Taught us about the Immortalization of Cancer Cells. , 2007, , 123-139.		0
90	Comparison of the Effects of Ras Effector Mutants and Ras Effectors on Transformed and Tumorigenic Growth of Human and Rodent Cells. , 2006, , 257-272.		0

#	Article	IF	Citations
91	Non-canonical genomic driver mutations of urethane carcinogenesis. PLoS ONE, 2022, 17, e0267147.	2.5	0
92	An ultra-sensitive method to detect mutations in human RAS templates. Small GTPases, 0, , .	1.6	0